Inhibitors of epoxide hydrolases for the treatment of inflammation

US8815951B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Bruce D. Hammock · Davis, US
• Jiang Zheng · Chongqing, CN
• Christophe Morisseau · West Sacramento, US
• Kazuhiko Motoba · Ibaraki, JP
• Mehran Moghaddam · Wilmington, US
• Babak Borhan · New York, US
• David F. Grant · Little Rock, US
• Jessica Greene · Oakland, US
• Marlene F. Sisemore · Davis, US
• James R. Sanborn · Modesto, US

Key dates

• Filing date: Dec 1, 2006
• Grant date: Aug 26, 2014
• Expiry date: Dec 1, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/66
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 is each independently C1-C20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.